The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy-Reference-Cited by-同舟云学术

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Published:2010-05 Issue:9 Volume:9 Page:1781-1791
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Abrams Stephen L.,Steelman Linda S.,Shelton John G.,Wong Ellis W.T.,Chappell William H.,Bäsecke Jörg,Stivala Franca,Donia Marco,Nicoletti Ferdinando,Libra Massimo,Martelli Alberto M.,McCubrey James A

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.4161/cc.9.9.11483

Reference56 articles.

1. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors;Carracedo;Cell Cycle,2008

2. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects;Krymskaya;Cell Cycle,2009

3. Targeting mTOR with rapamycin: one dose does not fit all;Foster;Cell Cycle,2009

4. Targeting prostate cancer based on signal transduction and cell cycle pathways;Lee;Cell Cycle,2008

5. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia;Steelman;Leukemia,2008

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy;BMC Cancer;2024-07-02

2. Synergistic anticancer effects of doxorubicin and metformin combination therapy: A systematic review;Translational Oncology;2024-07

3. Vitamin D Relieves Epilepsy Symptoms and Neuroinflammation in Juvenile Mice by Activating the mTOR Signaling Pathway via RAF1: Insights from Network Pharmacology and Molecular Docking Studies;Neurochemical Research;2024-06-05

4. Mechanism of miR-126 Loaded in Albumin Nanoparticles for Reversing the Multidrug Resistance in Breast Carcinoma Cells;Journal of Biomedical Nanotechnology;2024-06-01

5. Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways;Neoplasia;2024-05